CAS No.:36431-82-0

TOXICITY DATA with REFERENCE：

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
man	TDLo	intravenous	2300mg/kg/2D (2300mg/kg)	BLOOD: OXIDANT RELATED (GPD DEFICIENT) ANEMIA	Annals of Internal Medicine. Vol. 82, Pg. 810, 1975.
mouse	LD50	intraperitoneal	643mg/kg (643mg/kg)		Progress in Mutation Research. Vol. 1, Pg. 682, 1981.
mouse	LD50	intravenous	518mg/kg (518mg/kg)		Research Progress in Organic-Biological and Medicinal Chemistry. Vol. 2, Pg. 269, 1970.
mouse	LD50	oral	3367mg/kg (3367mg/kg)		National Cancer Institute Screening Program Data Summary, Developmental Therapeutics Program. Vol. JAN1986,
rat	LD50	intravenous	> 4gm/kg (4000mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Oyo Yakuri. Pharmacometrics. Vol. 12, Pg. 131, 1976.
rat	LD50	oral	11900mg/kg (11900mg/kg)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Oyo Yakuri. Pharmacometrics. Vol. 12, Pg. 131, 1976.
rat	LD50	subcutaneous	> 10gm/kg (10000mg/kg)		Oyo Yakuri. Pharmacometrics. Vol. 12, Pg. 131, 1976.
women	LDLo	intravenous	900mg/kg (900mg/kg)	KIDNEY, URETER, AND BLADDER: "CHANGES IN TUBULES (INCLUDING ACUTE RENAL FAILURE, ACUTE TUBULAR NECROSIS)"	Archives of Internal Medicine. Vol. 145, Pg. 950, 1985.

Consensus Reports：

 

SAFETY PROFILE：

 

Standards and Recommendations：

 

Analytical Methods：